Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 330 entries
Sorted by: Best Match Show Resources per page
Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran.

Przeglad gastroenterologiczny

Masjedizadeh A, Zaeemzadeh N, Mard SA, Vanani GS.
PMID: 26557940
Prz Gastroenterol. 2015;10(2):94-9. doi: 10.5114/pg.2015.49001. Epub 2015 Feb 10.

INTRODUCTION: Helicobacter pylori (H. pylori) is the common cause of many gastrointestinal diseases, especially peptic ulcer. Therefore, a successful treatment of this infection decreases the financial burden on health systems.AIM: Different combinations of antibiotics are used for the eradication...

Cite
Masjedizadeh A, Zaeemzadeh N, Mard SA, et al. Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran. Prz Gastroenterol. 2015;10(2):94-9doi: 10.5114/pg.2015.49001.
Masjedizadeh, A., Zaeemzadeh, N., Mard, S. A., & Vanani, G. S. (2015). Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran. Przeglad gastroenterologiczny, 10(2), 94-9. https://doi.org/10.5114/pg.2015.49001
Masjedizadeh, Abdolrahim, et al. "Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran." Przeglad gastroenterologiczny vol. 10,2 (2015): 94-9. doi: https://doi.org/10.5114/pg.2015.49001
Masjedizadeh A, Zaeemzadeh N, Mard SA, Vanani GS. Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran. Prz Gastroenterol. 2015;10(2):94-9. doi: 10.5114/pg.2015.49001. Epub 2015 Feb 10. PMID: 26557940; PMCID: PMC4631277.
Copy Download .nbib Format: NLM
Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.

Hereditary cancer in clinical practice

Huzarski T, Górecka-Szyld B, Huzarska J, Psut-Muszyńska G, Wilk G, Sibilski R, Cybulski C, Kozak-Klonowska B, Siołek M, Kilar E, Czudowska D, Janiszewska H, Godlewski D, Mackiewicz A, Jarkiewicz-Tretyn J, Szabo-Moskal J, Gronwald J, Lubiński J, Narod SA.
PMID: 28265306
Hered Cancer Clin Pract. 2017 Mar 01;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017.

BACKGROUND: The addition of MRI to mammography and ultrasound for breast cancer screening has been shown to improve screening sensitivity for high risk women, but there is little data to date for women at average or intermediate risk.METHODS: Two...

Cite
Huzarski T, Górecka-Szyld B, Huzarska J, et al. Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hered Cancer Clin Pract. 2017;15:4doi: 10.1186/s13053-017-0064-y.
Huzarski, T., Górecka-Szyld, B., Huzarska, J., Psut-Muszyńska, G., Wilk, G., Sibilski, R., Cybulski, C., Kozak-Klonowska, B., Siołek, M., Kilar, E., Czudowska, D., Janiszewska, H., Godlewski, D., Mackiewicz, A., Jarkiewicz-Tretyn, J., Szabo-Moskal, J., Gronwald, J., Lubiński, J., Narod, S. A. (2017). Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hereditary cancer in clinical practice, 154. https://doi.org/10.1186/s13053-017-0064-y
Huzarski, Tomasz, et al. "Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer." Hereditary cancer in clinical practice vol. 15 (2017): 4. doi: https://doi.org/10.1186/s13053-017-0064-y
Huzarski T, Górecka-Szyld B, Huzarska J, Psut-Muszyńska G, Wilk G, Sibilski R, Cybulski C, Kozak-Klonowska B, Siołek M, Kilar E, Czudowska D, Janiszewska H, Godlewski D, Mackiewicz A, Jarkiewicz-Tretyn J, Szabo-Moskal J, Gronwald J, Lubiński J, Narod SA. Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hered Cancer Clin Pract. 2017 Mar 01;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017. PMID: 28265306; PMCID: PMC5333437.
Copy Download .nbib Format: NLM
Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone.

Hereditary cancer in clinical practice

Galor A, Cybulski C, Lubiński J, Narod SA, Gronwald J.
PMID: 24325841
Hered Cancer Clin Pract. 2013 Dec 10;11(1):17. doi: 10.1186/1897-4287-11-17.

The effectiveness of a genetics-based public health screening programs depend on the successful recruitment of subjects who qualify for intensified screening by virtue of a positive genetic test. Herein we compare the effectiveness of a mailed invitation and follow-up...

Cite
Galor A, Cybulski C, Lubiński J, et al. Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone. Hered Cancer Clin Pract. 2013;11(1):17doi: 10.1186/1897-4287-11-17.
Galor, A., Cybulski, C., Lubiński, J., Narod, S. A., & Gronwald, J. (2013). Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone. Hereditary cancer in clinical practice, 11(1), 17. https://doi.org/10.1186/1897-4287-11-17
Galor, Anna, et al. "Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone." Hereditary cancer in clinical practice vol. 11,1 (2013): 17. doi: https://doi.org/10.1186/1897-4287-11-17
Galor A, Cybulski C, Lubiński J, Narod SA, Gronwald J. Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone. Hered Cancer Clin Pract. 2013 Dec 10;11(1):17. doi: 10.1186/1897-4287-11-17. PMID: 24325841; PMCID: PMC3904754.
Copy Download .nbib Format: NLM
Have we given up on a cure for ovarian cancer?.

Current oncology (Toronto, Ont.)

, Narod SA.
PMID: 26089723
Curr Oncol. 2015 Jun;22(3):e139-41. doi: 10.3747/co.22.2517.

No abstract available.

Cite
, Narod SA. Have we given up on a cure for ovarian cancer?. Curr Oncol. 2015;22(3):e139-41doi: 10.3747/co.22.2517.
, & Narod, S. A. (2015). Have we given up on a cure for ovarian cancer?. Current oncology (Toronto, Ont.), 22(3), e139-41. https://doi.org/10.3747/co.22.2517
, and Narod, S A. "Have we given up on a cure for ovarian cancer?." Current oncology (Toronto, Ont.) vol. 22,3 (2015): e139-41. doi: https://doi.org/10.3747/co.22.2517
, Narod SA. Have we given up on a cure for ovarian cancer?. Curr Oncol. 2015 Jun;22(3):e139-41. doi: 10.3747/co.22.2517. PMID: 26089723; PMCID: PMC4462534.
Copy Download .nbib Format: NLM
Dispersion of the third-order nonlinear optical properties of an organometallic dendrimer(1).

Journal of the American Chemical Society

Powell CE, Morrall JP, Ward SA, Cifuentes MP, Notaras EG, Samoc M, Humphrey MG.
PMID: 15453734
J Am Chem Soc. 2004 Oct 06;126(39):12234-5. doi: 10.1021/ja048608l.

The dispersion of cubic nonlinearity in the organometallic dendrimer 1,3,5-(3,5-{trans-[(dppe)2(4-O2NC6H4CC)RuCC]}2C6H3CCC6H4-4-CC)3C6H3 can be understood in terms of an interplay of two-photon absorption and absorption saturation. Simple dispersion relations reproduce the behavior of both the real and imaginary components of the...

Cite
Powell CE, Morrall JP, Ward SA, et al. Dispersion of the third-order nonlinear optical properties of an organometallic dendrimer(1). J Am Chem Soc. 2004;126(39):12234-5doi: 10.1021/ja048608l.
Powell, C. E., Morrall, J. P., Ward, S. A., Cifuentes, M. P., Notaras, E. G., Samoc, M., & Humphrey, M. G. (2004). Dispersion of the third-order nonlinear optical properties of an organometallic dendrimer(1). Journal of the American Chemical Society, 126(39), 12234-5. https://doi.org/10.1021/ja048608l
Powell, Clem E, et al. "Dispersion of the third-order nonlinear optical properties of an organometallic dendrimer(1)." Journal of the American Chemical Society vol. 126,39 (2004): 12234-5. doi: https://doi.org/10.1021/ja048608l
Powell CE, Morrall JP, Ward SA, Cifuentes MP, Notaras EG, Samoc M, Humphrey MG. Dispersion of the third-order nonlinear optical properties of an organometallic dendrimer(1). J Am Chem Soc. 2004 Oct 06;126(39):12234-5. doi: 10.1021/ja048608l. PMID: 15453734.
Copy Download .nbib Format: NLM
The prevention of hereditary breast and ovarian cancer: a personal view.

Hereditary cancer in clinical practice

Narod S.
PMID: 20233484
Hered Cancer Clin Pract. 2004 Feb 15;2(1):5-10. doi: 10.1186/1897-4287-2-1-5.

Options for the prevention of hereditary breast and ovarian cancer include screening, preventive surgery and chemoprevention. Screening studies with magnetic resonance imaging of the breast are promising but the technology is not widespread and MRI is unlikely to be...

Cite
Narod S. The prevention of hereditary breast and ovarian cancer: a personal view. Hered Cancer Clin Pract. 2004;2(1):5-10doi: 10.1186/1897-4287-2-1-5.
Narod, S. (2004). The prevention of hereditary breast and ovarian cancer: a personal view. Hereditary cancer in clinical practice, 2(1), 5-10. https://doi.org/10.1186/1897-4287-2-1-5
Narod, Steven. "The prevention of hereditary breast and ovarian cancer: a personal view." Hereditary cancer in clinical practice vol. 2,1 (2004): 5-10. doi: https://doi.org/10.1186/1897-4287-2-1-5
Narod S. The prevention of hereditary breast and ovarian cancer: a personal view. Hered Cancer Clin Pract. 2004 Feb 15;2(1):5-10. doi: 10.1186/1897-4287-2-1-5. PMID: 20233484; PMCID: PMC2839994.
Copy Download .nbib Format: NLM
Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer.

Hereditary cancer in clinical practice

Narod SA.
PMID: 20223019
Hered Cancer Clin Pract. 2006 Dec 15;4(4):167-8. doi: 10.1186/1897-4287-4-4-167.

No abstract available.

Cite
Narod SA. Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer. Hered Cancer Clin Pract. 2006;4(4):167-8doi: 10.1186/1897-4287-4-4-167.
Narod, S. A. (2006). Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer. Hereditary cancer in clinical practice, 4(4), 167-8. https://doi.org/10.1186/1897-4287-4-4-167
Narod, Steven A. "Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer." Hereditary cancer in clinical practice vol. 4,4 (2006): 167-8. doi: https://doi.org/10.1186/1897-4287-4-4-167
Narod SA. Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer. Hered Cancer Clin Pract. 2006 Dec 15;4(4):167-8. doi: 10.1186/1897-4287-4-4-167. PMID: 20223019; PMCID: PMC2837304.
Copy Download .nbib Format: NLM
The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs.

Hereditary cancer in clinical practice

Lubiński J, Huzarski T, Kurzawski G, Suchy J, Masojć B, Mierzejewski M, Lener M, Domagała W, Chosia M, Teodorczyk U, Medrek K, Debniak T, Złowocka E, Gronwald J, Byrski T, Grabowska E, Nej K, Szymańska A, Szymańska J, Matyjasik J, Cybulski C, Jakubowska A, Górski B, Narod SA.
PMID: 20223031
Hered Cancer Clin Pract. 2005 Mar 15;3(2):59-63. doi: 10.1186/1897-4287-3-2-59.

The NOD2 gene has been associated with susceptibility to Crohn's disease and individuals with Crohn's disease are at increased risk for cancer at a number of organ sites. We studied the association between the 3020insC allele of the NOD2...

Cite
Lubiński J, Huzarski T, Kurzawski G, et al. The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hered Cancer Clin Pract. 2005;3(2):59-63doi: 10.1186/1897-4287-3-2-59.
Lubiński, J., Huzarski, T., Kurzawski, G., Suchy, J., Masojć, B., Mierzejewski, M., Lener, M., Domagała, W., Chosia, M., Teodorczyk, U., Medrek, K., Debniak, T., Złowocka, E., Gronwald, J., Byrski, T., Grabowska, E., Nej, K., Szymańska, A., Szymańska, J., Matyjasik, J., Cybulski, C., Jakubowska, A., Górski, B., & Narod, S. A. (2005). The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hereditary cancer in clinical practice, 3(2), 59-63. https://doi.org/10.1186/1897-4287-3-2-59
Lubiński, Jan, et al. "The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs." Hereditary cancer in clinical practice vol. 3,2 (2005): 59-63. doi: https://doi.org/10.1186/1897-4287-3-2-59
Lubiński J, Huzarski T, Kurzawski G, Suchy J, Masojć B, Mierzejewski M, Lener M, Domagała W, Chosia M, Teodorczyk U, Medrek K, Debniak T, Złowocka E, Gronwald J, Byrski T, Grabowska E, Nej K, Szymańska A, Szymańska J, Matyjasik J, Cybulski C, Jakubowska A, Górski B, Narod SA. The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hered Cancer Clin Pract. 2005 Mar 15;3(2):59-63. doi: 10.1186/1897-4287-3-2-59. PMID: 20223031; PMCID: PMC2837299.
Copy Download .nbib Format: NLM
Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series.

Current oncology (Toronto, Ont.)

Narod SA.
PMID: 21980244
Curr Oncol. 2011 Oct;18(5):204-5. doi: 10.3747/co.v18i5.938.

No abstract available.

Cite
Narod SA. Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series. Curr Oncol. 2011;18(5):204-5doi: 10.3747/co.v18i5.938.
Narod, S. A. (2011). Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series. Current oncology (Toronto, Ont.), 18(5), 204-5. https://doi.org/10.3747/co.v18i5.938
Narod, S A. "Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series." Current oncology (Toronto, Ont.) vol. 18,5 (2011): 204-5. doi: https://doi.org/10.3747/co.v18i5.938
Narod SA. Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series. Curr Oncol. 2011 Oct;18(5):204-5. doi: 10.3747/co.v18i5.938. PMID: 21980244; PMCID: PMC3185894.
Copy Download .nbib Format: NLM
Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent BRCA1/2 Mutations.

Journal of cancer epidemiology

Bissonauth V, Shatenstein B, Fafard E, Maugard C, Robidoux A, Narod S, Ghadirian P.
PMID: 20445803
J Cancer Epidemiol. 2009;2009:748367. doi: 10.1155/2009/748367. Epub 2009 Apr 16.

Several lifestyle factors play a significant role in determining an individual's risk of breast cancer. Many of them could be modified to protect against the malignancy. A nested case-control study was conducted to examine the association between selected lifestyle...

Cite
Bissonauth V, Shatenstein B, Fafard E, et al. Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent BRCA1/2 Mutations. J Cancer Epidemiol. 2009;2009:748367doi: 10.1155/2009/748367.
Bissonauth, V., Shatenstein, B., Fafard, E., Maugard, C., Robidoux, A., Narod, S., & Ghadirian, P. (2009). Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent BRCA1/2 Mutations. Journal of cancer epidemiology, 2009748367. https://doi.org/10.1155/2009/748367
Bissonauth, Vishnee, et al. "Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent BRCA1/2 Mutations." Journal of cancer epidemiology vol. 2009 (2009): 748367. doi: https://doi.org/10.1155/2009/748367
Bissonauth V, Shatenstein B, Fafard E, Maugard C, Robidoux A, Narod S, Ghadirian P. Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent BRCA1/2 Mutations. J Cancer Epidemiol. 2009;2009:748367. doi: 10.1155/2009/748367. Epub 2009 Apr 16. PMID: 20445803; PMCID: PMC2859024.
Copy Download .nbib Format: NLM
Personalized medicine: a personal view.

Current oncology (Toronto, Ont.)

Narod SA.
PMID: 20975871
Curr Oncol. 2010 Oct;17(5):4-5. doi: 10.3747/co.v17i5.587.

No abstract available.

Cite
Narod SA. Personalized medicine: a personal view. Curr Oncol. 2010;17(5):4-5doi: 10.3747/co.v17i5.587.
Narod, S. A. (2010). Personalized medicine: a personal view. Current oncology (Toronto, Ont.), 17(5), 4-5. https://doi.org/10.3747/co.v17i5.587
Narod, S A. "Personalized medicine: a personal view." Current oncology (Toronto, Ont.) vol. 17,5 (2010): 4-5. doi: https://doi.org/10.3747/co.v17i5.587
Narod SA. Personalized medicine: a personal view. Curr Oncol. 2010 Oct;17(5):4-5. doi: 10.3747/co.v17i5.587. PMID: 20975871; PMCID: PMC2949368.
Copy Download .nbib Format: NLM
Ensure a greater visibility to the international research community.

Contact lens & anterior eye : the journal of the British Contact Lens Association

Naroo SA.
PMID: 22564374
Cont Lens Anterior Eye. 2012 Jun;35(3):99. doi: 10.1016/j.clae.2012.03.003.

No abstract available.

Cite
Naroo SA. Ensure a greater visibility to the international research community. Cont Lens Anterior Eye. 2012;35(3):99doi: 10.1016/j.clae.2012.03.003.
Naroo, S. A. (2012). Ensure a greater visibility to the international research community. Contact lens & anterior eye : the journal of the British Contact Lens Association, 35(3), 99. https://doi.org/10.1016/j.clae.2012.03.003
Naroo, Shehzad A. "Ensure a greater visibility to the international research community." Contact lens & anterior eye : the journal of the British Contact Lens Association vol. 35,3 (2012): 99. doi: https://doi.org/10.1016/j.clae.2012.03.003
Naroo SA. Ensure a greater visibility to the international research community. Cont Lens Anterior Eye. 2012 Jun;35(3):99. doi: 10.1016/j.clae.2012.03.003. PMID: 22564374.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 330 entries